State Street Corporation filed a Schedule 13G with the SEC on November 10, 2026, disclosing beneficial ownership of 1,772,302 shares of Nektar Therapeutics common stock as of September 30, 2026.

Key Highlights

  • Aggregate beneficial ownership: State Street Corporation reported beneficial ownership of 1,772,302 shares of Nektar Therapeutics common stock.
  • Percent of class: The reported stake represents 5.2% of the outstanding class of common stock, according to the filing.
  • Shared voting power: State Street disclosed shared voting power over 1,699,729 shares, with zero sole voting power.
  • Shared dispositive power: The filing reports shared dispositive power over 1,772,302 shares, with zero sole dispositive power.
  • Triggering date: The event requiring the filing occurred on September 30, 2026.
  • Subsidiaries involved: The filing identifies SSGA Funds Management, Inc., State Street Global Advisors Europe Limited, State Street Global Advisors Limited, State Street Global Advisors Trust Company, and State Street Global Advisors, Ltd. as the relevant investment adviser subsidiaries.

State Street's Schedule 13G Filing on Nektar Therapeutics Common Stock

State Street Corporation, a holding company organized in Massachusetts and headquartered at One Congress Street, Suite 1, Boston, MA 02114, filed a Schedule 13G disclosing its position in Nektar Therapeutics (NASDAQ:NKTR), whose principal executive offices are located at 455 Mission Bay Blvd, South San Francisco, California, 94158. The filing was submitted on November 10, 2026, with a triggering event date of September 30, 2026, based on CUSIP number 640268306.

According to the filing, State Street reported aggregate beneficial ownership of 1,772,302 shares, constituting 5.2% of the class. The company disclosed no sole voting power and no sole dispositive power over any of those shares. Shared voting power covered 1,699,729 shares, while shared dispositive power extended to the full 1,772,302 shares reported. State Street is classified as a parent holding company (type "HC") in the filing.

The filing lists five subsidiaries through which the position is held, all classified as investment advisers (IA): SSGA Funds Management, Inc.; State Street Global Advisors Europe Limited; State Street Global Advisors Limited; State Street Global Advisors Trust Company; and State Street Global Advisors, Ltd. The filing was signed by Alok Maheshwary, Senior Vice President, on November 9, 2026. State Street certified that the securities "were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer."

What Was Disclosed

State Street Corporation disclosed a 5.2% beneficial ownership position, representing 1,772,302 shares of Nektar Therapeutics common stock, held through five investment adviser subsidiaries as of September 30, 2026, with all voting and dispositive power held on a shared basis.